SEC Tracker
Get the app

Spero Therapeutics SPRO

Spero Therapeutics (SPRO) announced the resignation of its Chief Executive Officer, effective immediately, citing strategic differences with the Board of Directors. This unexpected leadership change introduces uncertainty and potential disruption to the company's ongoing clinical programs and commercialization efforts, which could impact shareholder value.

Form
8-K
Filed
Importance
Major

Open in the appGet the appView on EDGAR

Get an email when Spero Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lineage Cell Therapeutics LCTX public float $162M, Jun 30, 2025
  2. Forte Biosciences FBRX public float $157M, Jun 30, 2025
  3. Monopar Therapeutics MNPR public float $156M, Jun 30, 2025
  4. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025
  5. XOMA Royalty XOMA public float $168M, Jun 30, 2025